EMA Withdrawn: Xiapex (collagenase Clostridium histolyticum) — Swedish Orphan Biovitrum AB

View source ↗

Summary

The EMA has withdrawn Xiapex (collagenase Clostridium histolyticum) from the market for Dupuytren Contracture by Swedish Orphan Biovitrum AB.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dupuytren Contracture

Drugs mentioned

• Xiapex (collagenase clostridium histolyticum)

Snippet

Status: Withdrawn. Therapeutic area: Dupuytren Contracture. MAH: Swedish Orphan Biovitrum AB. Decision date: 28/11/2019